IRIS
MINARI, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.073
NA - Nord America 929
AS - Asia 497
AF - Africa 24
SA - Sud America 4
OC - Oceania 2
Totale 2.529
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 918
IT - Italia 445
SG - Singapore 227
IE - Irlanda 211
CN - Cina 185
SE - Svezia 161
DE - Germania 46
AT - Austria 33
FI - Finlandia 32
FR - Francia 31
IN - India 24
CI - Costa d'Avorio 23
GB - Regno Unito 23
NL - Olanda 19
CZ - Repubblica Ceca 18
HK - Hong Kong 18
TR - Turchia 18
CA - Canada 11
RU - Federazione Russa 9
BE - Belgio 8
LU - Lussemburgo 6
JP - Giappone 5
UA - Ucraina 5
AR - Argentina 4
IR - Iran 4
LT - Lituania 4
RO - Romania 4
ES - Italia 3
MK - Macedonia 3
PK - Pakistan 3
AU - Australia 2
BG - Bulgaria 2
DK - Danimarca 2
ID - Indonesia 2
IL - Israele 2
MD - Moldavia 2
PL - Polonia 2
VN - Vietnam 2
AZ - Azerbaigian 1
CH - Svizzera 1
HR - Croazia 1
HU - Ungheria 1
KR - Corea 1
KZ - Kazakistan 1
MY - Malesia 1
NO - Norvegia 1
PH - Filippine 1
TW - Taiwan 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 2.529
Salva come PNG Salva come JPEG
Città #
Dublin 206
Chandler 200
Singapore 166
Parma 122
Boardman 96
Ashburn 90
Ann Arbor 84
Shanghai 73
Milan 60
Vienna 32
New York 31
Beijing 27
Chicago 27
Marseille 27
Abidjan 23
Princeton 22
Verona 22
Bologna 21
Dearborn 16
West Jordan 16
Helsinki 15
Bremen 14
Munich 14
Brno 13
Hong Kong 12
Los Angeles 12
Izmir 11
London 11
Amsterdam 10
Des Moines 10
Santa Clara 10
Wilmington 10
Brussels 8
Pune 8
Dallas 7
Fremont 7
Jinan 7
Modena 7
Ravenna 7
Auburn 6
Frankfurt am Main 6
Kolkata 6
Pavia 6
Redmond 6
Rome 6
Shenyang 6
Woodbridge 6
Bolzano 5
Changsha 5
Istanbul 5
Nanchang 5
Nanjing 5
Seattle 5
Toronto 5
Bottanuco 4
Buenos Aires 4
Busseto 4
Cascina 4
Central 4
Ferrara 4
Hefei 4
Jacksonville 4
Olomouc 4
Salsomaggiore Terme 4
Trento 4
Wayne 4
Casalgrande 3
Castellarano 3
Coimbatore 3
Florence 3
Guangzhou 3
Houston 3
Kunming 3
Kyiv 3
Lonato 3
Manchester 3
Norwalk 3
Redwood City 3
Rubiera 3
San Giuliano Milanese 3
Alcamo 2
Ayr 2
Bagnolo in Piano 2
Boston 2
Brusaporto 2
Candiac 2
Carpenedolo 2
Chiari 2
Chisinau 2
Desio 2
Dong Ket 2
Fairfield 2
Genoa 2
Gioia Tauro 2
Hayamiya 2
Hebei 2
Karak 2
Leawood 2
Luxembourg 2
Madrid 2
Totale 1.767
Salva come PNG Salva come JPEG
Nome #
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 125
Evidence fo Epigenetic Abnormalities of the Androgen Receptor Gene in Foreskin from Children with Hypospadias 120
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 111
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 84
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 80
A novel mutation in the nr0b1 gene in a family with monozygotic twin sisters and congenital adrenal hypoplasia affected children. 79
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 78
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 78
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 76
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 76
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC 72
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 71
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 68
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 66
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 66
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 64
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 64
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 64
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition 63
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 63
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 56
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 55
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 54
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 53
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 49
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 49
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights 47
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 45
227P Sexual dimorphism in immune profile of early and advanced NSCLC 45
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 43
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 43
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 40
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 40
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 38
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 35
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: Review on emerged mechanisms of resistance 35
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 31
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 27
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer 27
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 25
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 24
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 20
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 20
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 19
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 18
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review 16
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents 15
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 15
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 14
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 12
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC 11
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 11
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 11
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 9
Totale 2.620
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.339
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.339
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020100 0 0 0 0 6 15 20 7 12 21 14 5
2020/2021102 3 5 2 5 3 5 12 10 20 8 14 15
2021/2022215 19 8 10 16 11 2 43 10 17 3 20 56
2022/2023849 67 84 37 73 83 87 15 64 242 7 61 29
2023/2024656 30 24 15 28 58 89 62 35 36 70 86 123
2024/2025587 101 105 144 152 85 0 0 0 0 0 0 0
Totale 2.620